In some critical areas, we remain at risk. Antiviral agents are potentially life-saving tools. Many developed countries have substantial stockpiles of oseltamivir. Most isolates tested to date have been reported to be sensitive to both oseltamivir and zanamivir, but 1 isolate, A/Shanghai/1/2013, contains the R294K mutation in neuraminidase that can confer oseltamivir resistance (9). Emergence of resistance to oseltamivir would greatly limit treatment options, especially for more severely ill patients. Zanamivir is likely to remain an active option, but supplies are limited and the inhaled powder formulation restricts use in some populations. Intravenous preparations of zanamivir and peramivir are in advanced development, and a sialidase fusion construct (DAS181) is in phase 2 study, but this is a slim pipeline (10). We need to develop more treatment options, including agents that could modify the inflammatory cascade and treat secondary infections.